Parabilis Medicines, Inc.
▲ 1 upgrades / ▼ 0 downgrades / 0 reiterations from 1 firms
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 22, 2026 | HC Wainwright & Co. | initiate | — → Buy | — | 44% |
| Jul 6, 2026 | Guggenheim | initiate | — → Buy | — | 52% |
| Jul 6, 2026 | Leerink Partners | initiate | — → Outperform | — | 51% |
| Jul 6, 2026 | B of A Securities | initiate | — → Buy | — | 53% |
No cross-platform signals in the last 90 days